Michael Gelband’s Sana Biotechnology SANA Stock Holding History

Michael Gelband’s Portfolio SANA Stock Details SANA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-61,659	Closed	-$178K	–	2000
2026 Q1	$178K	Buy	+61,659	New	+$243K	﹤0.01%	1394
2025 Q3	–	Sell	-71,401	Closed	-$195K	–	1954
2025 Q2	$195K	Buy	+71,401	New	+$147K	﹤0.01%	1317
2025 Q1	–	Sell	-272,908	Closed	-$445K	–	1936
2024 Q4	$445K	Buy	272,908 +173,442	+174%	+$517K	﹤0.01%	1177
2024 Q3	$414K	Buy	+99,466	New	+$523K	﹤0.01%	1258
2023 Q4	–	Sell	-22,226	Closed	-$86K	–	1979
2023 Q3	$86K	Buy	+22,226	New	+$119K	﹤0.01%	1594
2023 Q1	–	Sell	-58,569	Closed	-$231K	–	2083
2022 Q4	$231K	Sell	58,569 -50,070	-46%	-$245K	﹤0.01%	1425
2022 Q3	$652K	Buy	+108,639	New	+$784K	0.01%	1276
2022 Q2	–	Sell	-72,557	Closed	-$599K	–	2381
2022 Q1	$599K	Buy	72,557 +46,246	+176%	+$374K	0.01%	1431
2021 Q4	$407K	Buy	+26,311	New	+$507K	﹤0.01%	1525

Other funds holding SANA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marex Group London $23.6B AUM 57.16% 1-Year Est. Return

Michael Gelband's SANA Position: Q2 2026 in Review

Michael Gelband sold out of Sana Biotechnology (SANA) in Q2 2026, closing a stake of 61,659 shares — an estimated $178K sold.

Michael Gelband first reported a position in SANA in Q4 2021 and held it in 9 quarters. The position peaked at $652K in Q3 2022. 208 funds tracked by Wall St. Rank hold SANA as of Q2 2026.

Michael Gelband reported no remaining Sana Biotechnology position as of Q2 2026 after selling out during the quarter.
Michael Gelband sold 61,659 Sana Biotechnology shares in Q2 2026, an estimated $178K.
Michael Gelband first reported a position in Sana Biotechnology in Q4 2021 and held it in 9 quarters.
Michael Gelband's Sana Biotechnology position peaked at $652K in Q3 2022.
208 funds tracked by Wall St. Rank held Sana Biotechnology as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.